TransMedics price to book ratio TMDX
Market value divided by the book value of the company's net assets, since 2019.
- Today, Oct 23, 2026
- 4.7×
- 7-year median
- 10.1×
- Against its 7-year history
- 7th
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 2.9× to 31.5×
- Peer median
- 2.0×
TransMedics' price to book ratio is 4.7× as of Oct 23, 2026.
That is below its 7-year median of 10.1×, lower than on 93% of days in the last 7 years.
Over that time it ranged from 2.9× in Oct 2020 to 31.5× in Jul 2024.
The median for 4 medical device stocks of a similar size is 2.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 4.7× | 4.4× | 13.8× |
| 2025 | 11.9× | 9.1× | 18.2× |
| 2024 | 9.8× | 9.8× | 31.5× |
| 2023 | 20.4× | 8.5× | 20.4× |
| 2022 | 10.5× | 5.1× | 30.9× |
| 2021 | 6.8× | 4.7× | 11.7× |
| 2020 | 4.9× | 2.9× | 8.3× |
| 2019 | 6.2× | 5.0× | 7.3× |
Against its peers
Companies in Medical - Devices nearest TransMedics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| TMDXTransMedics | 4.7× |
| CNMDCONMED | 1.4× |
| ITGRInteger | 2.5× |
| LIVNLivaNova | 3.4× |
| ZBHZimmer Biomet | 1.5× |
| Peer median | 2.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on TransMedics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.